Decision-Aiding System Improves Clinical Trial Performance
The CCI-CPP collaborative team announces the newest release of Country Allocation Planner? (CAP), a Web-based system for global clinical trial planning.??
DECISION-AIDING SYSTEM IMPROVES CLINICAL TRIAL PERFORMANCE
ATLANTA, GA June 19, 2008 – The CCI-CPP collaborative team announces the newest release of Country Allocation Planner™ (CAP), a Web-based system for global clinical trial planning. CAP improves clinical trial enrollment forecasting and the process of selecting countries for study participation by facilitating robust, unlimited and real-time “what if” scenario modeling.
“Fundamentally, CAP helps study planning teams forecast realistic enrollment times and select the optimum mix of countries and subject contributions to meet key operational objectives, like cycle time and cost,” says Beth Harper of Clinical Performance Partners, Inc.
The design for the system is a result of a collaborative effort between Core Concept, Inc., specialists in software, simulation and decision support, and Clinical Performance Partners, Inc. a provider of enrollment and site performance management services. CAP uses industry data on disease prevalence as well as internal company benchmark data, and then incorporates enrollment feasibility data to plan, manage and update enrollment projections.
CAP’s linear programming and advanced data modeling capabilities allow planning across multiple parameters, such as number of countries and investigative sites, enrollment rate, subject contribution, disease prevalence, and per subject cost. This breadth of enrollment planning is generally not feasible for most users engaged in global clinical trials.
“Our user-friendly system ensures that all available information and advanced analysis techniques are combined to provide the sponsor or contract research organization (CRO) with insight into the best possible scenarios for enrollment success,” states Rob Andes, Executive Vice President of Core Concept. CAP does not make decisions, rely on team assumptions to make arbitrary enrollment projections or force the user to adhere to a set workflow.
Want to learn more or schedule a demo? Contact Rob Andes at 678/772-7181 or email [email protected].
About Clinical Performance Partners - CPP is a consulting firm dedicated to designing and implementing innovative and practical solutions for improving site performance and accelerating clinical trials results for the Life Sciences Industry. www.clinicalperformancepartners.com
About Core Concept, Inc. – CCI is a software product company specializing in the development of advanced decision support systems for the analysis, forecasting, planning and management of clinical trials and payor management. www.coreconcept.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
